IR Overview

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). Our lead program, utilizing our NY-ESO TCR therapeutic, has a promising risk/benefit profile to date in Phase I/II trials in solid tumors and in hematologic cancer types. We continue to build a pipeline of TCR therapeutic candidates targeting a number of additional cancer targets, including our MAGE-A10 therapy which has entered initial clinical studies.

$4.21 Stock is Up 0.16 (3.95%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume80,220
Today's Open$4.05
Previous Close$4.05
Data as of 12/05/16 3:59 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
12/05/16Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY‑ESO SPEAR™ T‑cells in myxoid/round cell liposarcoma (MRCLS). Patient screening is underway, and the results from this study in up to 15 patients will inform a potential future registration trial. The initiation of screening in this study meets a milestone set forth in the Compan... 
Printer Friendly Version
11/11/16Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)
PHILADELPHIA and OXFORD, United Kingdom, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation with updated data on its study of NY‑ESO SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T‑cells in the ongoing synovial sarcoma trial at the 2016 Connective Tissue Oncology Society (CTOS) annual meeting presented by Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center. This p... 
Printer Friendly Version
11/11/16Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the presentation of data at the 2016 Society for Immunotherapy for Cancer (SITC) annual meeting. The posters summarize: (1) preclinical data from Adaptimmune’s wholly-owned MAGE-A4 SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T‑cells; (2) preclinical data from the Company’s second generation SPEAR T-cell, whic... 
Printer Friendly Version
11/10/16Adaptimmune Reports Third Quarter 2016 Financial Results
– U.S. Food and Drug Administration (FDA) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 – – Initiated first site for triple tumor study with wholly-owned MAGE-A10 SPEAR T-cells – – Initiated new patient cohort in synovial sarcoma NY-ESO program – – Started recruitment of additional patients under amended protocol in ovarian NY-ESO program – – Executed key agreements with Merck, PCT, a... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.